Dynamic profiling technique offers personalized approach to lung cancer treatment

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication. The use of inhibitors against this oncogene—one of the most effective strategies against this type of cancer—has benefited many patients. But, is it possible to know if the treatment will be effective in all those affected?